FGFR1 and cancer: Future efforts that consider combination therapeutic strategies may overcome the limitations of single-agent FGFR inhibition in FGFR1 amplified cancers, might serve as a potential clinical approach for enhancing efficacy and minimizing unexpected outcomes [58].